Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment

Preclinical models in HNSCC: A comprehensive review

(2017) Benoite Méry et al.   ORAL ONCOLOGY

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

(2017) et al.   JAMA Oncology

HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment

(2016) Stefan Hartmann et al.   CLINICAL CANCER RESEARCH

Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation

(2016) Guoqing Qian et al.   EUROPEAN JOURNAL OF CANCER

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

(2016) Laura Q.M. Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

E-cadherin expression and prognosis of head and neck squamous cell carcinoma: evidence from 19 published investigations

(2016) Xusheng Ren et al.   OncoTargets and Therapy

Alteration status and prognostic value of MET in head and neck squamous cell carcinoma

(2016) Yoon Ah Cho et al.   Journal of Cancer

Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma

(2015) Wei-Hong Xi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

(2015) A. Dimitrios Colevas   Journal of the National Comprehensive Cancer Network

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

(2015) Juan Madoz-Gúrpide et al.   Journal of Translational Medicine

Comprehensive genomic characterization of head and neck squamous cell carcinomas

(2015)   NATURE

Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti–Hepatocyte Growth Factor Antibody Ficlatuzumab

(2015) Dhruv Kumar et al.   JAMA Otolaryngology-Head & Neck Surgery

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer

(2014) N Takahashi et al.   BRITISH JOURNAL OF CANCER

Targeting the c-Met/FZD8 Signaling Axis Eliminates Patient-Derived Cancer Stem-like Cells in Head and Neck Squamous Carcinomas

(2014) S. Sun et al.   CANCER RESEARCH

LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

(2014) L. Liu et al.   CLINICAL CANCER RESEARCH

Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus–negative tonsillar squamous cell carcinoma and their prognostic significances

(2014) Mi Jung Kwon et al.   HUMAN PATHOLOGY

c-Met Expression Is a Marker of Poor Prognosis in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Treated With Chemoradiation

(2014) Andrew M. Baschnagel et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines

(2014) Antonio Calles et al.   Molecular Oncology

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck

(2014) Dan P. Zandberg et al.   ORAL ONCOLOGY

Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer

(2014) Lluís Nisa et al.   PHARMACOLOGY & THERAPEUTICS

MET Genetic Abnormalities Unreliable for Patient Selection for Therapeutic Intervention in Oropharyngeal Squamous Cell Carcinoma

(2014) Ludovic Lacroix et al.   PLoS One

TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells

(2014) ELAINE YUE LING WONG et al.   Oncology Letters

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

(2014) M. Hidalgo et al.   Cancer Discovery

Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models

(2013) Sarah Elizabeth Wheeler et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

HGF–MET Cascade, a Key Target for Inhibiting Cancer Metastasis: The Impact of NK4 Discovery on Cancer Biology and Therapeutics

(2013) Shinya Mizuno et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas

(2013) D. Basu et al.   MOLECULAR CANCER THERAPEUTICS

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

(2013) Stephen B. Keysar et al.   Molecular Oncology

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

(2013) M. Merchant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met

(2012) L. P. Stabile et al.   CLINICAL CANCER RESEARCH

Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies

(2012) Lisa Licitra et al.   EUROPEAN JOURNAL OF CANCER

Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

(2012) Tanguy Seiwert et al.   INVESTIGATIONAL NEW DRUGS

Overcoming resistance to EGFR inhibitor in head and neck cancer: A review of the literature

(2012) Guilherme Rabinowits et al.   ORAL ONCOLOGY

Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells

(2011) H. Xu et al.   CLINICAL CANCER RESEARCH

Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer

(2011) Ranee Mehra et al.   DRUG RESISTANCE UPDATES

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance

(2011) Rebekka Krumbach et al.   EUROPEAN JOURNAL OF CANCER

Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer

(2011) Tadaaki Yamada et al.   Journal of Thoracic Oncology

Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells

(2011) L. Liu et al.   MOLECULAR CANCER THERAPEUTICS

c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase

(2011) R Szabo et al.   ONCOGENE

Cetuximab Therapy for Head and Neck Squamous Cell Carcinoma

(2011) Travis D. Reeves et al.   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

The role of human papillomavirus infection in head and neck cancers

(2010) S. Syrjanen   ANNALS OF ONCOLOGY

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

(2010) L. Licitra et al.   ANNALS OF ONCOLOGY

Novel therapeutic target for head and neck squamous cell carcinoma

(2010) Patrick Chi-pan Lau et al.   ANTI-CANCER DRUGS

Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs

(2010) Hidenori Tanaka et al.   INTERNATIONAL JOURNAL OF CANCER

TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation

(2010) W. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

Molecular Therapy Targeting Sonic Hedgehog and Hepatocyte Growth Factor Signaling in a Mouse Model of Medulloblastoma

(2010) V. Coon et al.   MOLECULAR CANCER THERAPEUTICS

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

(2010) K. Kian Ang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death

(2010) V W Y Lui et al.   ONCOGENE

Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice

(2010) Laura P. Stabile et al.   Cancers

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

(2009) T. Y. Seiwert et al.   CANCER RESEARCH

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

(2009) F. Qian et al.   CANCER RESEARCH

MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers

(2009) Pirus Ghadjar et al.   CLINICAL & EXPERIMENTAL METASTASIS

HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer

(2009) L. M. Knowles et al.   CLINICAL CANCER RESEARCH

Prognostic value of c-Met expression in oral squamous cell carcinoma

(2009) Freudlsperger   Experimental and Therapeutic Medicine

Molecular Pathology of Head and Neck Cancer: Implications for Diagnosis, Prognosis, and Treatment

(2008) Sara I. Pai et al.   Annual Review of Pathology-Mechanisms of Disease

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

(2008) Jan. B. Vermorken et al.   CANCER

Tumor–stroma interactions influence cytokine expression and matrix metalloproteinase activities in paired primary and metastatic head and neck cancer cells

(2008) S KOONTONGKAEW et al.   CELL BIOLOGY INTERNATIONAL

Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis

(2008) L. P. Stabile et al.   MOLECULAR CANCER THERAPEUTICS

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma

(2007) Maria-Jantine De Herdt   Frontiers in Bioscience-Landmark